5 Best Buy-the-Dip Stocks to Invest In Now

2. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 12 best buy-the-dip stocks to invest in now.

On June 10, an underwritten public offering of common stock valued at $500 million was initiated by Summit Therapeutics Inc. (NASDAQ:SMMT). The company stated in its announcement that 100% of the shares in this proposed transaction are being offered directly by Summit. To manage and coordinate the equity issuance process, the firm has appointed J.P. Morgan, Goldman Sachs & Co., and Citigroup to serve as the joint book-running managers.

On June 1, following the presentation of Phase 3 HARMONi-6 trial data at an ASCO plenary session, Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT). As a first-line treatment for squamous non-small cell lung cancer (NSCLC), the China-based research evaluated the combination of ivonescimab and chemotherapy versus tislelizumab plus chemotherapy.

The ivonescimab combination produced a median progression-free survival (PFS) of 11 months and a hazard ratio of 0.60, according to previously published results at ESMO 2025. Overall survival (OS) data were still in their infancy at the time. Cantor pointed out that worries about whether PFS enhancements will eventually result in an OS benefit in the first-line scenario are addressed by the interim OS data from HARMONi-6.

The main question at hand is whether the Phase 3 HARMONi-3 trial, which is comparing ivonescimab with chemotherapy versus pembrolizumab plus chemotherapy in first-line NSCLC, can repeat these favorable results worldwide. The second part of 2026 is when results are expected. Although the speaker acknowledged that HARMONi-6 showed efficacy in China, concerns were raised during the ASCO discussion about the regimen’s suitability for patients in the United States.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a clinical-stage biopharma company that develops and commercializes medical oncology therapies. It is focused on developing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis in a single molecule. It is also running Phase III clinical trials for the treatment of non-small lung cancer.